Johnson & JohnsonJohnson & Johnson
Siemens HealthineersSiemens Healthineers
Merz TherapeuticsMerz Therapeutics
MerckMerck
RocheRoche
Boehringer IngelheimBoehringer Ingelheim
City of HopeCity of Hope
GenentechGenentech
LivaNovaLivaNova
NovartisNovartis
UCBUCB

Patent expiries put more than $200 billion of branded revenue at risk before 2030, and drugmakers have to refill their pipelines while the rules change in Washington, Brussels and Beijing at once. Four shifts set the pharma agenda for 2027 and beyond.

  1. Price pressure hits both sides of the Atlantic. All 17 large drugmakers in the US pricing deals promised launch prices no higher than in other developed countries, Medicare negotiates prices for 15 more drugs from January 2027, and the EU pharma package cuts baseline data protection to eight years.

  2. China turns from fast follower into a source of new medicines. Chinese biotechs licensed out assets worth about $110 billion in the first half of 2026, and Chinese partners account for 38% of big pharma's licensing deals.

  3. Factories follow trade policy. The US charges tariffs of up to 100% on imported patented medicines since 29 September 2026, and branded drugmakers have announced roughly $500 billion in US investment.

  4. More medicines work for months or years after a single dose. Twice-yearly injections prevent HIV, Lilly's base editor VERVE-102 cut LDL cholesterol by up to 62% after one infusion, and big pharma bought companies that make CAR-T cells inside the patient's body.

The ITONICS pharma radar below maps all 71 trends across six segments of the pharma value chain, from discovery to the patient.

Explore the pharma trend radar 2027+

The interactive ITONICS pharma trend radar 2027+: Trends are rated by time to impact, from 0-2 to 8-10 years, and by potential impact, from low to very high. 8 of 71 rate very high.

Pharma trends to watch in 2027 and beyond

The radar holds 71 trends that move at very different speeds. Some reshape budgets within two years, some hinge on a trial result or a law with a known date, and a few take most of the next decade.

  • Act on now. Four very-high-impact trends land within two years: China as big pharma's largest external source of new molecules, US tariffs that make local production a condition of market access, US pressure on European prices and the collapse in obesity drug prices.

  • Dates to watch. The first BIOSECURE list is due by December 2026, Medicare's negotiated prices for 15 more drugs start in January 2027, PBM delinking in Medicare Part D follows in January 2028, and EU joint clinical assessments extend to orphan medicines in 2028.

  • Against the consensus. Obesity drugs turn into a volume business, quantum computing stays a research bet for drug discovery, and gene therapy's commercial model breaks before its science does.

  • Quiet costs. EU wastewater charges, PFAS restrictions, new inhaler propellants and NHS supply chain carbon reporting add cost and supply risk.

  • Long bets. Eighteen trends sit six to ten years out, from in vivo CAR-T and one-time gene editing to brain shuttles and genome sequencing at birth.

Discovery and preclinical research trends 2027+

Big pharma now buys a large share of its early pipeline from outside, with Chinese partners behind 38% of large pharma licensing deals, and AI moves deeper into the lab. The eleven discovery trends also cover venture funding, AI-run labs and rejuvenation therapies. Three discovery trends stand out:

Summary: Western drugmakers license a large share of their new clinical assets from Chinese biotechs, at rising prices. Chinese developers lead in antibody-drug conjugates, bispecifics and obesity programmes, and pipeline strategy shifts from internal discovery toward sourcing with geopolitical risk priced in.

Current situation: Out-licensing deals from greater China reached a record $137.7 billion in total value in 2025, according to Pharmcube data cited by Reuters, and China's drug regulator reported about $110 billion for the first half of 2026. Average upfronts for China-sourced deals rose from $52 million in 2022 to $172 million in early 2026, and Chinese partners account for 38% of large pharma licensing deals.

Expected development: Licensing keeps rising as patent expiries force big pharma to refill late-decade pipelines. Deals adapt through split regional rights, NewCo vehicles and manufacturing outside China, and the first BIOSECURE designations decide whether the flow continues on current terms.

Challenges: Data from China-only trials may not satisfy FDA and EMA without Western patients, and national security scrutiny is rising in Washington. Rising upfronts compress returns, and crowded targets invite duplicated bets.

Time to impact: 0-2 years

Potential impact: Very high

STEEP segment: Economic

Signals to watch:

  • 31 Dec 2026: OMB publishes the first BIOSECURE list of biotechnology companies of concern
  • 31 Jan 2027: Full-year 2026 out-licensing value from greater China is published
  • 31 Jul 2027: China's drug regulator reports out-licensing value for the first half of 2027
ITONICS trend card with a line illustration and the Insights tab open, showing signals to watch for the trend China becomes big pharma's largest external source of new molecules: 31 Dec 2026, OMB publishes the first BIOSECURE list of biotechnology companies of concern. Accelerates if: The list names China-based CROs and CDMOs that serve Western licensees. Stalls if: The list stays narrow and spares licensing partners. Source: OMB; 31 Jan 2027, Full-year 2026 out-licensing value from greater China is published. Accelerates if: Deal value tops the 2025 record of $137.7 billion. Stalls if: Deal value falls back below the 2025 record. Source: Pharmcube; 31 Jul 2027, China's drug regulator reports out-licensing value for the first half of 2027. Accelerates if: Value passes the roughly $110 billion of the first half of 2026. Stalls if: Value drops as buyers wait for BIOSECURE clarity. Source: NMPA
Exhibit 1: Signals to watch for China-sourced drug licensing in ITONICS

Clinical development trends 2027+

Some trials get shorter while others get longer: residual-disease endpoints, digital twins and first-in-human studies in China speed development, while prevention drugs need outcome trials with thousands of patients. Three clinical development trends stand out:

Summary: GLP-1-based drugs now carry outcome labels beyond weight loss, and next-generation agonists approach the weight loss of surgery. Competition moves to tolerability, muscle preservation and outcome data across organs, and payers face a class that touches cardiology, nephrology, hepatology and sleep medicine at once.

Current situation: Semaglutide is approved for cardiovascular risk reduction, kidney protection in type 2 diabetes and MASH, and tirzepatide for obstructive sleep apnoea. Lilly's triple agonist retatrutide produced 28.3% average weight loss at 80 weeks in TRIUMPH-1, and in July 2026 TRIUMPH-3 showed 22.6% in people with severe obesity and heart disease. Lilly plans to file retatrutide with the FDA in the first quarter of 2027.

Expected development: Outcome trials in heart failure, kidney and liver disease expand labels and payer acceptance through 2028. Differentiation shifts to tolerability, dosing, lean mass and maintenance after weight loss.

Challenges: Gastrointestinal side effects and discontinuation limit real-world persistence, and long-term safety of very large weight loss needs more data. Payers struggle to fund chronic use across so many indications.

Time to impact: 2-4 years

Potential impact: Very high

STEEP segment: Technological

Signals to watch:

  • 1 Jan 2027: Medicare's negotiated semaglutide price of $274 takes effect
  • 31 Mar 2027: Lilly files retatrutide with the FDA
  • 30 Jun 2027: The ADA Scientific Sessions bring maintenance and lean-mass data
ITONICS trend card with a line illustration and the Insights tab open, showing signals to watch for the trend Incretin drugs grow from obesity treatments into a multi-organ franchise: 1 Jan 2027, Medicare's negotiated semaglutide price of $274 takes effect. Accelerates if: Medicare volume rises as the price falls. Stalls if: Plans restrict access despite the lower price. Source: CMS; 31 Mar 2027, Lilly files retatrutide with the FDA. Accelerates if: The filing covers obesity, knee osteoarthritis pain and sleep apnoea. Stalls if: Manufacturing data delay the filing again. Source: Eli Lilly; 30 Jun 2027, The ADA Scientific Sessions bring maintenance and lean-mass data. Accelerates if: Data show weight held after dose reduction. Stalls if: Discontinuation and side effects dominate the data. Source: ADA
Exhibit 2: Signals to watch for the incretin drug franchise in ITONICS

Regulatory and approval trends 2027+

Regulators in the US and Europe rewrite the rules at the same time, each in its own direction, while new routes open for AI-generated evidence, analytically approved biosimilars and single-patient gene editing. Three regulatory trends stand out:

Summary: Both major markets are cutting the period in which a new medicine earns its return undisturbed. The EU pharma package lowers baseline regulatory protection, and US Medicare negotiation reaches small molecules seven years after approval and biologics after eleven.

Current situation: The EU's provisional agreement of 11 December 2025 replaces the 8+2+1 formula with eight years of data protection plus one year of market protection, conditional extensions and a cap of 11 years, and formal adoption is pending. Medicare negotiated prices for the first ten drugs took effect in January 2026, 15 more including semaglutide follow in January 2027, and the 2028 cycle brings Part B drugs into negotiation.

Expected development: Products filed before the 24-month cut-off keep the old protection periods, so the full EU effect lands on launches toward the end of the decade. Companies design programmes around the extension criteria, and the US gap between small molecules and biologics tilts portfolios toward biologics.

Challenges: Protection now differs by market, modality and indication, which complicates launch sequencing and asset valuation. Industry keeps lobbying to close the US small-molecule gap.

Time to impact: 2-4 years

Potential impact: Very high

STEEP segment: Political

Signals to watch:

  • 1 Jan 2027: Medicare negotiated prices for 15 more drugs take effect
  • 1 Feb 2027: CMS selects up to 20 Part B and D drugs for prices that start in 2029
  • 30 Jun 2027: The EU formally adopts the pharma package
ITONICS trend card with a line illustration and the Insights tab open, showing signals to watch for the trend Europe and the US shorten effective exclusivity for new medicines: 1 Jan 2027, Medicare negotiated prices for 15 more drugs take effect. Accelerates if: Net prices fall sharply for the selected products. Stalls if: Manufacturers offset the cuts elsewhere in their portfolios. Source: CMS; 1 Feb 2027, CMS selects up to 20 Part B and D drugs for prices that start in 2029. Accelerates if: The list includes more large biologics. Stalls if: Selection stays concentrated on older small molecules. Source: CMS; 30 Jun 2027, The EU formally adopts the pharma package. Accelerates if: Eight years of data protection apply to filings after the cut-off. Stalls if: Adoption slips and the old protection periods hold longer. Source: Council of the EU
Exhibit 3: Signals to watch for shorter exclusivity in Europe and the US in ITONICS

Manufacturing and supply chain trends 2027+

Where medicines are made has turned into a political decision: tariffs pull branded production into the US, generic injectables keep running short, and environmental rules add pressure from inhaler propellants to supplier carbon reporting. Three manufacturing and supply chain trends stand out:

Summary: The US taxes imported patented medicines and their ingredients at up to 100% unless companies produce locally or hold pricing deals. Branded drugmakers answered with roughly $500 billion in announced US investment, while generics and several specialty categories remain exempt for now.

Current situation: Proclamation 11020 of 2 April 2026 imposed Section 232 tariffs on patented pharmaceuticals, their active ingredients and key starting materials, applying from 31 July 2026 for 17 named large manufacturers and from 29 September 2026 for all other importers. Generics, biosimilars, orphan drugs, cell and gene therapies and antibody-drug conjugates are exempt, and UK-origin products are exempt until January 2029.

Expected development: Much of the announced capacity is due by 2030, which shifts branded API and fill-finish toward the US and leaves European and Asian sites to serve generics and ex-US markets. Patent status becomes a customs question, and generic tariffs deferred until 2028 extend the pressure.

Challenges: New biologics plants take years to build and validate, so tariffs bite before capacity exists. Tariff terms can change through litigation, bilateral deals or a new administration.

Time to impact: 0-2 years

Potential impact: Very high

STEEP segment: Political

Signals to watch:

  • 28 Feb 2027: Large drugmakers report 2026 results with US capex and tariff costs
  • 30 Jun 2027: The first announced US plants for branded API and fill-finish start operations
  • 1 Jan 2028: Deferred tariffs on generic medicines fall due
ITONICS trend card with a line illustration and the Insights tab open, showing signals to watch for the trend Tariffs turn US manufacturing capacity into a condition of market access: 28 Feb 2027, Large drugmakers report 2026 results with US capex and tariff costs. Accelerates if: Companies raise US capacity commitments beyond $500 billion. Stalls if: Companies slow announced US projects. Source: Company reports; 30 Jun 2027, The first announced US plants for branded API and fill-finish start operations. Accelerates if: Plants open on schedule and volumes shift to the US. Stalls if: Projects slip toward 2030. Source: Company reports; 1 Jan 2028, Deferred tariffs on generic medicines fall due. Accelerates if: Washington applies the generic tariffs. Stalls if: The deferral is extended. Source: US Commerce
Exhibit 4: Signals to watch for US tariffs on medicines in ITONICS

Market access and pricing trends 2027+

Pricing carries the most immediate risk on the radar, with three of the eight very-high-impact trends here, and Medicare's PBM reform and EU joint clinical assessments change how net prices and launch evidence work. Three market access and pricing trends stand out:

Summary: Most-favoured-nation pricing ties US launch prices to those in other rich countries, so companies push for higher prices abroad or delay launches there. The UK raised its NICE threshold for the first time since 1999, and other European payers face a choice between paying more and waiting longer.

Current situation: Under the UK-US pharmaceutical deal of December 2025, the UK secured zero tariffs on drug exports to the US and raised NICE's threshold from £20,000 to £30,000 per QALY to £25,000 to £35,000 from April 2026. The UK committed to raise medicines spending toward 0.6% of GDP and to cut the VPAG rebate rate to 15% in 2026, and all 17 large drugmakers in the US deals committed to launch prices no higher than in other developed countries.

Expected development: Companies hold back launches in low-price European markets unless prices rise, which pressures Germany, France, Italy and Spain to revise pricing rules or accept slower access. Confidential rebates grow in importance.

Challenges: Higher prices strain European health budgets, and delayed launches provoke political backlash. US policy could change after 2028, leaving Europe with commitments that outlast the pressure.

Time to impact: 0-2 years

Potential impact: Very high

STEEP segment: Economic

Signals to watch:

  • 31 Dec 2026: The UK sets the 2027 VPAG rebate rate
  • 30 Jun 2027: EFPIA's W.A.I.T. report shows launch delays across Europe
  • 13 Jan 2028: EU joint clinical assessments extend to orphan medicines
ITONICS trend card with a line illustration and the Insights tab open, showing signals to watch for the trend US pressure forces Europe to pay more for new medicines, starting with the UK: 31 Dec 2026, The UK sets the 2027 VPAG rebate rate. Accelerates if: The rate stays near the promised 15%. Stalls if: The rate rises above 15%. Source: DHSC; 30 Jun 2027, EFPIA's W.A.I.T. report shows launch delays across Europe. Accelerates if: Delays grow in low-price markets. Stalls if: Launch times hold steady. Source: EFPIA; 13 Jan 2028, EU joint clinical assessments extend to orphan medicines. Accelerates if: More launches face comparative evidence demands. Stalls if: Assessments stay limited in scope. Source: European Commission
Exhibit 5: Signals to watch for US pressure on European drug prices in ITONICS

Commercialization and patient engagement trends 2027+

Commercial models change faster than any other part of the value chain, with six of eleven trends landing within two years, and diagnosis moves earlier through blood tests and genome sequencing at birth. Three commercialization trends stand out:

Summary: Manufacturer cash-pay channels have moved from niche programmes to federally promoted infrastructure. TrumpRx, launched in February 2026, routes patients to company offers at most-favoured-nation prices, which gives manufacturers patient relationships and exposes net prices the rebate system used to hide.

Current situation: All 17 large drugmakers approached by the White House in July 2025 signed MFN deals, which the administration says cover about 86% of the branded US market. TrumpRx launched with around 40 products and listed more than 800 by August 2026, and in August ten pharmacy benefit managers committed to show TrumpRx cash prices in prescribers' real-time benefit tools.

Expected development: Direct channels extend from obesity and primary-care brands to specialty products with high out-of-pocket costs. PBM economics come under pressure as cash prices appear at the point of prescribing.

Challenges: Cash purchases may not count toward insurance deductibles, and Reuters found many TrumpRx prices above those paid in the UK. The deals are voluntary, so their durability depends on politics.

Time to impact: 0-2 years

Potential impact: High

STEEP segment: Economic

Signals to watch:

  • 31 Mar 2027: Ten PBMs show TrumpRx cash prices in prescribers' real-time benefit tools
  • 30 Jun 2027: Congress acts on the request to codify most-favoured-nation pricing
  • 1 Jan 2028: PBM delinking takes effect in Medicare Part D
ITONICS trend card with a line illustration and the Insights tab open, showing signals to watch for the trend Drugmakers sell direct to patients and bypass the PBM channel: 31 Mar 2027, Ten PBMs show TrumpRx cash prices in prescribers' real-time benefit tools. Accelerates if: Cash prices appear for most branded prescriptions. Stalls if: Display stays limited to a few products. Source: White House; 30 Jun 2027, Congress acts on the request to codify most-favoured-nation pricing. Accelerates if: Congress writes MFN pricing into law. Stalls if: The deals stay voluntary. Source: US Congress; 1 Jan 2028, PBM delinking takes effect in Medicare Part D. Accelerates if: PBM pay moves to flat fees and rebates shrink. Stalls if: Implementation slips. Source: CMS
Exhibit 6: Signals to watch for direct-to-patient drug sales in ITONICS

Download all 71 pharma trends with current situation, expected development, challenges and ratings for your next portfolio review or strategy workshop.

Download all 71 pharma trends 2027+

In ITONICS, R&D, strategy and business development teams rate the trends with their own experts and link each one to the programmes it affects.

FAQs on pharma industry trends 2027+

Check your portfolio against these trends on one platform

See it early. Kill it fast. Fill the pipeline before the cliff.